Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver MutationsJustin A. Chen, Jonathan W. Riess|Current Treatment Options in Oncology|2020Cited by 23
Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitorsJustin A. Chen, Jonathan W. Riess|Journal of Thoracic Disease|2020Cited by 20
A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancerJustin A. Chen, Edward Kim, Jonathan W. Riess et al.|Cancer Chemotherapy and Pharmacology|2022Cited by 7